arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2024-2435RCPKHQarthyper-2435Research ArticleСтатьиArticlesКонтроль артериальной гипертензии и продвижения пациента по сердечно‑сосудистому континууму на фоне фиксированной комбинации амлодипина и периндоприла А: фокус на эндотелий, метаболические рискиControlling blood pressure and progression of hypertension-dependent cardiovascular continuum by amlodipine and perindopril A single pill fixed‑dose combination: focus on endothelial dysfunction and metabolic riskshttps://orcid.org/0000-0001-9546-7049СвеклинаТ. С.SveklinaT. S.

Свеклина Татьяна Сергеевна — кандидат медицинских наук, доцент кафедры пропедевтики внутренних болезней

Суворовский пр., 63а, Санкт-Петербург, 191124

Tatiana S. Sveklina, MD, PhD, Associate Professor, Internal Diseases Propadeutics Department

Suvorovsky av., 63a, St Petersburg, 191124

sveklina@rambler.ruhttps://orcid.org/0000-0003-2888-9625КучминА. Н.KuchminA. N.

Кучмин Алексей Николаевич — доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней

Санкт-Петербург

Alexey N. Kuchmin, MD, PhD, DSc, Head and Professor, Department of Propedeutics of Internal Diseases

St Petersburg

kuchmin.63@mail.ruhttps://orcid.org/0000-0002-8347-2286КоняевВ. В.KonyaevV. V.

Коняев Владислав Вячеславович — студент 6-го курса 

Санкт-Петербург

Vladislav V. Konyaev, the 6th Year Student

St Petersburg

konyaevvladislav@yandex.ruhttps://orcid.org/0000-0003-1956-2110ОктысюкП. Д.OktysyukP. D.

Октысюк Полина Дмитриевна — студент 6-го курса 

Санкт-Петербург

 

Polina D. Oktysyuk, the 6th Year Student

St Petersburg

polinaok99@gmail.comhttps://orcid.org/0000-0002-3542-9013РечкаловаА. И.RechkalovaA. I.

Речкалова Алина Игоревна — студент 6-го курса 

Санкт-Петербург

Alina I. Rechkalova, the 6th Year Student

St Petersburg

alinarechkalova@mail.ruФедеральное государственное бюджетное военное образовательное учреждение высшего образования «Военно-медицинская академия имени С. М. Кирова» Министерства обороны Российской ФедерацииРоссияS. M. Kirov Military Medical AcademyRussian Federation202429042024302224231Copyright © Свеклина Т.С., Кучмин А.Н., Коняев В.В., Октысюк П.Д., Речкалова А.И., 20242024Свеклина Т.С., Кучмин А.Н., Коняев В.В., Октысюк П.Д., Речкалова А.И.Sveklina T.S., Kuchmin A.N., Konyaev V.V., Oktysyuk P.D., Rechkalova A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2435

Использование фиксированных комбинаций в терапии артериальной гипертензии (АГ) зарекомендовало себя в качестве эталонного первичного звена за счет разнопланового патогенетического воздействия на все этапы АГ-ассоциированного сердечно-сосудистого континуума. В основе последнего лежит функциональная несостоятельность эндотелия различного генеза, ввиду чего именно сочетание блокаторов кальциевых каналов и ингибиторов ангиотензинпревращающего фермента является оптимальным выбором. В обзоре представлены основные точки приложения фиксированной комбинации амлодипина и периндоприла А, определяющие ее место в современной идеологии ведения кардиологических пациентов. Особое внимание уделено метаболической нейтральности препарата, его способности нивелировать каскад уже имеющихся метаболических сдвигов у соответствующей касты пациентов. Кратко приведены данные основополагающих обсервационных и рандомизированных клинических исследований, изучающих эффективность составляющих препарата и его влияние на конечные точки. Сфокусировано внимание на вазои кардиопротективных свойствах амлодипина и периндоприла А, освещен профиль их безопасности.

Due to its broad spectrum of pathogenic target points, fixed-dose combination therapy is considered a benchmark approach to successful treatment of arterial hypertension (HTN) and HTN-associated cardiovascular conditions. This results from endothelium insufficiency of various origin, so the use of combination of angiotensinconverting enzyme inhibitors and calcium channel blockers is an optimal treatment choice. The review highlights key points of single pill amlodipine and perindopril A combination use and its key position in modern concept of hypertension management. We have focused on the metabolic neutrality of fixed-dose amlodipine and perindopril A combination, its ability to delay rapid progression of already acquired metabolic changes. We briefly highlight fundamental observational and randomized studies, in particular, those regarding effectiveness of the drug components and its effect on the end points as a fixed-dose combination. The last but not least, we emphasize vasoand cardioprotective properties of the drug as well as its safety profile.

артериальная гипертензиякомбинация препаратовсердечно-сосудистые заболеванияметаболические рискиhypertensioncombination of drugscardiovascular diseasesmetabolic risksReferencesКобалава Ж. Д., Конради А. О., Недогода С. В., Шляхто Е. В., Арутюнов Г. П., Баранова Е. И. и др. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786. In Russian.Dat TV, Tu VL, Thu LNA, Quang NNA, Binh V, Nga NTQ et al. Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review. Front Pharmacol. 2024;14:1156655. doi:10.3389/fphar.2023.1156655Dat TV, Tu VL, Thu LNA, Quang NNA, Binh V, Nga NTQ et al. Effectiveness of perindopril/amlodipine fixed-dose combination in the treatment of hypertension: a systematic review. Front Pharmacol. 2024;14:1156655. doi:10.3389/fphar.2023.1156655Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636. doi:10.1161/CIRCRESAHA.115.306301Gimbrone MA Jr, García-Cardeña G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res. 2016;118(4):620–636. doi:10.1161/CIRCRESAHA.115.306301Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules. 2019;9(8):301. doi:10.3390/biom9080301Malekmohammad K, Sewell RDE, Rafieian-Kopaei M. Antioxidants and atherosclerosis: mechanistic aspects. Biomolecules. 2019;9(8):301. doi:10.3390/biom9080301Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 Suppl):C7-C12. doi:10.1016/j.jacc.2005.09.068Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 Suppl):C7-C12. doi:10.1016/j.jacc.2005.09.068Singh S, Anshita D, Ravichandiran V. MCP 1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. doi:10.1016/j.intimp.2021.107598Singh S, Anshita D, Ravichandiran V. MCP 1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. doi:10.1016/j.intimp.2021.107598Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35(11):1039–1047. doi:10.1038/hr.2012.138Higashi Y, Kihara Y, Noma K. Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012;35(11):1039–1047. doi:10.1038/hr.2012.138Li R, Mi X, Yang S, Yang Y, Zhang S, Hui R et al. Longterm stimulation of angiotensin II induced endothelial senescence and dysfunction. Exp Gerontol. 2019;119:212–220. doi:10.1016/j.exger.2019.02.012Li R, Mi X, Yang S, Yang Y, Zhang S, Hui R et al. Longterm stimulation of angiotensin II induced endothelial senescence and dysfunction. Exp Gerontol. 2019;119:212–220. doi:10.1016/j.exger.2019.02.012Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2017;956:511–540. doi:10.1007/5584_2016_90Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Adv Exp Med Biol. 2017;956:511–540. doi:10.1007/5584_2016_90Kelly AS, Gonzalez-Campoy JM, Rudser KD, Katz H, Metzig AM, Thalin M et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich). 2012;14(2):85–91. doi:10.1111/j.1751-7176.2011.00569.xKelly AS, Gonzalez-Campoy JM, Rudser KD, Katz H, Metzig AM, Thalin M et al. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich). 2012;14(2):85–91. doi:10.1111/j.1751-7176.2011.00569.xFerrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixedcombination perindopril/amlodipine. Curr Med Res Opin. 2008;24(12):3543–3557. doi:10.1185/03007990802576302Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixedcombination perindopril/amlodipine. Curr Med Res Opin. 2008;24(12):3543–3557. doi:10.1185/03007990802576302Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924–967. doi:10.1124/pharmrev.120.000096Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X et al. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacol Rev. 2021;73(3):924–967. doi:10.1124/pharmrev.120.000096Meng J, Xiao G, Zhang J, He X, Ou M, Bi J et al. Reninangiotensin system inhibitors improve the clinical outcomes of COVID 19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.1746200Meng J, Xiao G, Zhang J, He X, Ou M, Bi J et al. Reninangiotensin system inhibitors improve the clinical outcomes of COVID 19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760. doi:10.1080/22221751.2020.1746200Benincasa G, Coscioni E, Napoli C. Cardiovascular risk factors and molecular routes underlying endothelial dysfunction: Novel opportunities for primary prevention. Biochem Pharmacol. 2022;202:115108. doi:10.1016/j.bcp.2022.115108Benincasa G, Coscioni E, Napoli C. Cardiovascular risk factors and molecular routes underlying endothelial dysfunction: Novel opportunities for primary prevention. Biochem Pharmacol. 2022;202:115108. doi:10.1016/j.bcp.2022.115108Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction novel roles of immunometabolism in macrophage activation and inflammation. Circ. Res. 2020;126:789– 806. doi:10.1161/CIRCRESAHA.119.312321Mouton AJ, Li X, Hall ME, Hall JE. Obesity, hypertension, and cardiac dysfunction novel roles of immunometabolism in macrophage activation and inflammation. Circ. Res. 2020;126:789– 806. doi:10.1161/CIRCRESAHA.119.312321Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020;35(4):389–396. doi:10.1097/HCO.0000000000000749Mendoza MF, Kachur SM, Lavie CJ. Hypertension in obesity. Curr Opin Cardiol. 2020;35(4):389–396. doi:10.1097/HCO.0000000000000749Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. Diabetologia. 2016;59(5):879–894. doi:10.1007/s00125-016-3904-9Boutens L, Stienstra R. Adipose tissue macrophages: going off track during obesity. Diabetologia. 2016;59(5):879–894. doi:10.1007/s00125-016-3904-9Liu R, Nikolajczyk BS. Tissue immune cells fuel obesityassociated inflammation in adipose tissue and beyond. Front Immunol. 2019;10:1587. doi:10.3389/fimmu.2019.01587Liu R, Nikolajczyk BS. Tissue immune cells fuel obesityassociated inflammation in adipose tissue and beyond. Front Immunol. 2019;10:1587. doi:10.3389/fimmu.2019.01587Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830. doi:10.1172/JCI19451Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–1830. doi:10.1172/JCI19451Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest. 2017;127(1):74–82. doi:10.1172/JCI88883Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest. 2017;127(1):74–82. doi:10.1172/JCI88883Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–2355. doi:10.1194/jlr.M500294-JLR200Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–2355. doi:10.1194/jlr.M500294-JLR200Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052 3056. doi:10.1161/hc5001.101061Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001;104(25):3052 3056. doi:10.1161/hc5001.101061Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117(25):3238–3249. doi:10.1161/CIRCULATIONAHA.107.741645Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117(25):3238–3249. doi:10.1161/CIRCULATIONAHA.107.741645Гриценко О. В., Чумакова Г. А., Груздева О. В., Шевляков И. В. Взаимосвязь эпикардиального ожирения и уровней маркеров фиброза миокарда. Российский кардиологический журнал. 2019;(4):13–19. doi:10.15829/1560-4071-2019-4-13-19Gritsenko OV, Chumakova GA, Gruzdeva OV, Shevlyakov IV. The relationship of epicardial obesity and levels of cardiac fibrosis markers. Russian Journal of Cardiology. 2019;(4):13–19. doi:10.15829/1560-4071-2019-4-13-19. In Russian.Mellor KM, Bell JR, Ritchie RH, Delbridge LM. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56–61. doi:10.1111/j.1440-1681.2012.05738.xMellor KM, Bell JR, Ritchie RH, Delbridge LM. Myocardial insulin resistance, metabolic stress and autophagy in diabetes. Clin Exp Pharmacol Physiol. 2013;40(1):56–61. doi:10.1111/j.1440-1681.2012.05738.xLi J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438–444. doi:10.1016/j.hrthm.2009.12.009Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm. 2010;7(4):438–444. doi:10.1016/j.hrthm.2009.12.009Ishii Y, Abe I, Kira S, Harada T, Takano M, Oniki T et al. Detection of fibrotic remodeling of epicardial adipose tissue in patients with atrial fibrillation: Imaging approach based on histological observation. Heart Rhythm O2. 2021;2(4):311–323. doi:10.1016/j.hroo.2021.05.006Ishii Y, Abe I, Kira S, Harada T, Takano M, Oniki T et al. Detection of fibrotic remodeling of epicardial adipose tissue in patients with atrial fibrillation: Imaging approach based on histological observation. Heart Rhythm O2. 2021;2(4):311–323. doi:10.1016/j.hroo.2021.05.006Потешкина Н. Г. Артериальная гипертензия и сахарный диабет: поиск оптимальной терапии — опыт применения периндоприла A/амлодипина. Российский кардиологический журнал. 2014;(12):64–70. doi:10.15829/1560-4071-2014-12-64-70Poteshkina NG. Arterial hypertension and diabetes mellitus: a quest for optimal treatment — an experience of perindopril A/ amlodipine usage. Russian Journal of Cardiology. 2014;(12):64–70. doi:10.15829/1560-4071-2014-12-64-70. In Russian.Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31(5):982–988. doi:10.2337/dc07-1768Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008;31(5):982–988. doi:10.2337/dc07-1768Marre M, Leye A. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity. Diab Vasc Dis Res. 2007;4(3):163–173. doi:10.3132/dvdr.2007.037Marre M, Leye A. Effects of perindopril in hypertensive patients with or without type 2 diabetes mellitus, and with altered insulin sensitivity. Diab Vasc Dis Res. 2007;4(3):163–173. doi:10.3132/dvdr.2007.037Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Br Med J. 2013;347: f6008. doi:10.1136/bmj.f6008Wu HY, Huang JW, Lin HJ, Liao WC, Peng YS, Hung KY et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. Br Med J. 2013;347: f6008. doi:10.1136/bmj.f6008Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557):201–207. doi:10.1016/S0140-6736(07)60108-1Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557):201–207. doi:10.1016/S0140-6736(07)60108-1Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503–1510. doi:10.1161/01.cir.102.13.1503Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503–1510. doi:10.1161/01.cir.102.13.1503Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2225. doi:10.1001/jama.292.18.2217Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–2225. doi:10.1001/jama.292.18.2217Werida R, Khairat I, Khedr L, El-Sisi AE. Comparative effects of enalapril versus perindopril on serum levels of leptin and adiponectin in hypertensive patients. Acta Cardiol. 2020;75(6):551– 556. doi:10.1080/00015385.2019.1636533Werida R, Khairat I, Khedr L, El-Sisi AE. Comparative effects of enalapril versus perindopril on serum levels of leptin and adiponectin in hypertensive patients. Acta Cardiol. 2020;75(6):551– 556. doi:10.1080/00015385.2019.1636533Bak JF, Gerdes LU, Sørensen NS, Pedersen O. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med. 1992;92(4B):69S 72S. doi:10.1016/0002-9343(92)90151-zBak JF, Gerdes LU, Sørensen NS, Pedersen O. Effects of perindopril on insulin sensitivity and plasma lipid profile in hypertensive non-insulin-dependent diabetic patients. Am J Med. 1992;92(4B):69S 72S. doi:10.1016/0002-9343(92)90151-zNedogoda SV, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013;33(8):553–561. doi:10.1007/s40261-013-0094-9Nedogoda SV, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013;33(8):553–561. doi:10.1007/s40261-013-0094-9Ueno S, Hamada T, Taniguchi S, Ohtani N, Miyazaki S, Mizuta E et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study. Drug Res (Stuttg). 2016;66(12):628–632. doi:10.1055/s-0042-113183Ueno S, Hamada T, Taniguchi S, Ohtani N, Miyazaki S, Mizuta E et al. Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study. Drug Res (Stuttg). 2016;66(12):628–632. doi:10.1055/s-0042-113183Nádházi Z, Dézsi CA. The results of ACES (Antihypertensive Combinations’ Long Term Efficacy Comparing Study): analysis of metabolic effects of antihypertensive combination therapies. Clin Drug Investig. 2016;36(10):819–827. doi:10.1007/s40261-016-0431-xNádházi Z, Dézsi CA. The results of ACES (Antihypertensive Combinations’ Long Term Efficacy Comparing Study): analysis of metabolic effects of antihypertensive combination therapies. Clin Drug Investig. 2016;36(10):819–827. doi:10.1007/s40261-016-0431-xНагорный М. Б., Кучмин А. Н. Обзор результатов ASCOT Legacy 20 лет. Российский кардиологический журнал. 2023;28(5):5457. doi:10.15829/1560-4071-2023-5457Nagorny MB, Kuchmin AN. Review of 20 year results of ASCOT Legacy. Russian Journal of Cardiology. 2023;28(5):5457. doi:10.15829/1560-4071-2023-5457. In Russian.

The authors declare that there are no conflicts of interest present.